AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 211 min read$IART

Integra LifeSciences Q3 Adjusted Earnings, Revenue Rise

Integra LifeSciences reported Q3 adjusted earnings and revenue growth. The company expects 2026 revenue between $1.63B and $1.65B, slightly below FactSet's estimate of $1.66B. The stock has seen a 5-day change of 13.33 USD and a year-to-date change of -3.75%.

Original reporting
marketscreener.com
Published Oct 21, 2026, 10:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
8/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The revenue shortfall relative to consensus may trigger short‑term sell pressure, but the adjusted earnings beat could soften the decline.

02

Market read

Earnings release is a primary catalyst for the stock and may influence the broader med‑tech sector.

03

What to watch

Potential upside from upcoming product launches not reflected in the current guidance.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Integra LifeSciences (IART) is a medical device and regenerative medicine company. The Q3 earnings release provides the latest financial performance metrics.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra LifeSciences reported Q3 adjusted earnings and a revenue range of $1.63B‑$1.65B, slightly below the $1.66B consensus.

Expected impact

likely pressure as the market prices in the revenue shortfall

Evidence & confidence

Revenue guidance undercuts consensus; investors typically react negatively to earnings below expectations.

Market effects

Sector

Medical device sector may see modest downside pressure from a key player missing revenue expectations.

Regional

U.S. healthcare stocks could see slight pullback in early trading.

Global

Limited to investors tracking U.S. med‑tech earnings season.

Counterpoint

What could challenge this read

If the company’s cost structure improves, the earnings beat could be a buying opportunity on a dip.

Key entities

  • Company
    Integra LifeSciences

    Medical device and regenerative medicine firm reporting Q3 results.

Read at source← All news

StoryIntegra LifeSciences reports Q3 2026 earnings, cites flood impact and revises Q4 outlook

Also covered by

6 outlets

Related articles

OCT 21
$IARTMed

Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

gurufocus.com3 min
OCT 21
$IARTHighAI 8/10

Integra (IART) Q3 2026 Earnings Call Transcript

Integra (IART) reported Q3 2026 adjusted EPS of $0.59, with revenue at $411.2M, impacted by Cincinnati flooding. Operating cash flow was $96M. Full-year revenue guidance was reduced by $30M due to flooding and mixed portfolio performance. Tissue Reconstruction revenue is expected to be flat. The company reduced leverage to 3.8x and completed debt refinancing, strengthening its balance sheet.

finance.yahoo.com3 min
OCT 21
$IARTHigh

Integra Life falls as tissue reconstruction woes add to flooding worries in Q3

Integra LifeSciences (IART) shares fell to a May low after Q3 2026 results missed revenue estimates. Revenue was $411.2M, up 2% YoY but below consensus by $0.9M, impacted by a $7M headwind and weaker Tissue Reconstruction performance. Gross margin declined 500 bps to 51%, while adjusted net income rose 12% YoY to $46.4M, beating estimates by $0.03 per share. Q4 and full-year outlooks were set below consensus.

tradingview.com2 min
OCT 21
Med

Integra LifeSciences Holdings Corporation Q3 2026 Earnings Call Summary

Integra LifeSciences reported Q3 2026 earnings, citing a $7M revenue hit from Cincinnati flooding. Neurosurgery grew 6.5% organically, offsetting weaker segments. Tissue Reconstruction showed mixed results. The company refinanced $2.1B in debt. Management expects 2027 revenue to be impacted by $15M-$20M in Q1 and Q2 due to ongoing disruption. Earnings growth is projected to be supported by cost savings and a SurgiMend relaunch.

finance.yahoo.com2 min